Advertisement: Simpsons Creative
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
Advertisement: partnersand mid banner
Cambridgeand mid banner advertisement
Barr Ellison Solicitors – commercial property
Advertisement: Kao Data Centre mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: EBCam mid banner
ARM Innovation Hub
Advertisement mid banner S-Tech 1
Advertisement: Cambridge Network mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: Mogrify mid banner
Mid banner advertisement: BDO
Advertisement: HCR Hewitsons mid banner
Advertisement: SATAVIA mid banner
20 January, 2022 - 13:10 By Tony Quested

Arecor starts Type 1 diabetes trial in US

Cambridge biopharma company Arecor Therapeutics plc has begun a US Phase 1 clinical trial of its lead product AT247 to treat Type 1 diabetes.

The potential solution is an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days. 

It is the first trial to investigate the product’s potential when delivered in this way and follows a previously successful first-in-man clinical study.

AT247, a novel proprietary formulation of insulin, aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes.

Arecor says it has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia.

In a European Phase I clinical study in Type I diabetic patients published in 2021, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with NovoRapid® and Fiasp®. 

This new trial is targeted for completion in H2 2022 and is expected to provide additional evidence that AT247 has the potential to facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes.

Arecor CEO Sarah Howell said: “We are excited to be initiating our first US clinical study that has been designed to further demonstrate the superiority of AT247 compared to current best-in-class insulins available to patients on the market today.

“Understanding the characteristics of AT247 when delivered via an infusion pump is important and may facilitate a fully closed loop artificial pancreas, transforming the lives of the c.537 million people living with diabetes.”

Newsletter Subscription

Stay informed of the latest news and features